What Is Cagrilintide? The Amylin Analog in Research

Cagrilintide is a long-acting analogue of amylin, the hormone the pancreas releases alongside insulin after a meal to signal fullness. Developed by Novo Nordisk under the code name AM833, it is chemically re-engineered so that a molecule the body normally clears in minutes circulates for about a week, and it is one of the most closely watched compounds in metabolic research because of that redesign.

Amylin biology sat at the edge of drug development for decades: the native hormone aggregates too readily and disappears too fast to be practical. Cagrilintide is the current answer to both problems, and its trial program, including a phase 2 monotherapy study and the phase 3 REDEFINE trials of its combination with semaglutide, is a matter of public record. It remains investigational and is not approved anywhere. This guide explains what cagrilintide is, how it was engineered, what the trials found, where the evidence stops, and how researchers verify the material.

What Is Amylin, and Why Build an Analogue of It?

Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells in response to food. Its job is to complete the satiety picture that insulin starts: amylin signaling slows gastric emptying, tempers post-meal glucagon release, and acts on brainstem circuits, including the area postrema, that register fullness and end a meal.

Two properties blocked amylin itself from becoming a durable research and development platform. First, human amylin is strongly amyloidogenic: it misfolds and aggregates, a behavior implicated in the islet amyloid found in type 2 diabetes. Second, its circulating half-life is short. The first-generation analogue pramlintide solved the aggregation problem with proline substitutions borrowed from rat amylin, but it still cleared quickly. Cagrilintide starts from that pramlintide-style backbone and adds the missing piece: duration.

• Class: Long-acting amylin analogue; dual amylin and calcitonin receptor agonist (DACRA)
• Developer / code name: Novo Nordisk / AM833
• Built from: Human amylin (IAPP), with a pramlintide-derived, aggregation-resistant backbone
• Key engineering: C20 fatty-diacid side chain attached at the N-terminal lysine, enabling reversible albumin binding
• Reported half-life: Approximately 159 to 195 hours (about 7 to 8 days) in trial pharmacokinetics
• Status (November 2026): Investigational; not approved as a medicine anywhere

How Was Cagrilintide Engineered to Last a Week?

The substitutions in cagrilintide's sequence do the quiet work: they keep the molecule soluble and suppress the self-assembly that makes native amylin clump. The headline modification is the fatty-acid side chain. Like the acylation strategy used in modern GLP-1 medicines, the attached C20 fatty diacid binds reversibly to albumin, the abundant carrier protein in blood. Albumin-bound cagrilintide is shielded from rapid clearance and released gradually, which stretches the half-life from minutes to roughly a week.

That pharmacokinetic profile is the entire design goal. In the clinical program, cagrilintide was studied on a once-weekly schedule, matching the rhythm researchers and developers had already established for weekly GLP-1 receptor agonists. For the laboratory, the same property makes cagrilintide a distinct object of study from native amylin: it is a case study in how acylation and sequence editing convert a fleeting signal into a sustained one, without changing the receptor message the molecule delivers.

At the receptor level, cagrilintide activates amylin receptors, which are complexes of the calcitonin receptor with receptor activity-modifying proteins, and it retains activity at the calcitonin receptor itself, hence the dual-agonist label. Downstream, the signaling converges on the same satiety and gastric-emptying pathways that native amylin engages after a meal.

How Does Cagrilintide Differ from GLP-1 Receptor Agonists?

Feature	Cagrilintide	Semaglutide (GLP-1 RA)	Pramlintide
Hormone basis	Amylin (IAPP)	GLP-1	Amylin (IAPP)
Receptor targets	Amylin receptors + calcitonin receptor	GLP-1 receptor	Amylin receptors
Approximate half-life	159–195 hours	About 1 week	Under 1 hour
Schedule studied	Once weekly	Once weekly	With meals
Development status	Investigational; phase 3 combination data published	Approved medicine (not a research chemical context)	Approved medicine for diabetes in the US

The comparison explains the combination strategy. GLP-1 and amylin signaling are complementary rather than redundant: they arise from different organs, act through different receptors, and converge on appetite and post-meal glucose control from different directions. A fixed combination, cagrilintide plus semaglutide, was therefore a rational experiment, and it is the form in which most of the phase 3 evidence was generated. Our Retatrutide research guide covers the other major multi-pathway design in current metabolic research, a single molecule engaging three receptors at once.

What Did the Phase 2 Monotherapy Trial Find?

The anchor study for cagrilintide alone is the phase 2 dose-finding trial published by Lau and colleagues in The Lancet in 2021. It randomized 706 adults with overweight or obesity across cagrilintide doses from 0.3 mg to 4.5 mg once weekly, placebo, and an active comparator, daily liraglutide 3.0 mg, over 26 weeks. The design makes it the cleanest public read on what the molecule does by itself.

The results were dose-dependent. Mean body-weight reduction ranged from about 6.0 percent at the lowest dose to about 10.8 percent at 4.5 mg, against about 3.0 percent on placebo. The 4.5 mg arm slightly exceeded the liraglutide comparator, which produced about 9.0 percent. Gastrointestinal effects were the most commonly reported adverse events, consistent with the amylin pathway's role in gastric emptying. These are outcomes from a sponsor-run clinical trial in a defined study population; they describe the investigational drug candidate, not any research chemical.

What Is CagriSema, and What Did REDEFINE Show?

CagriSema is the fixed combination of cagrilintide 2.4 mg with semaglutide 2.4 mg. In REDEFINE 1, published in the New England Journal of Medicine in 2025, 3,417 adults with obesity, or overweight with a weight-related condition and no diabetes, were followed for 68 weeks. The combination produced a mean weight reduction of about 20.4 percent, against about 3.0 percent on placebo, counting everyone who started treatment. REDEFINE 2, run in adults with type 2 diabetes, reported about 13.7 percent against about 3.4 percent over the same period.

Novo Nordisk submitted CagriSema to the United States Food and Drug Administration in December 2025, and a decision was still pending as of this writing in November 2026. A dedicated phase 3 program for cagrilintide monotherapy (the RENEW trials) has begun but has not reported results. In balance, the program also has a documented shortfall: REDEFINE 4, a head-to-head comparison announced in February 2026, did not show CagriSema to be non-inferior to tirzepatide 15 mg. The record, in other words, is strong but not unbroken, and it belongs almost entirely to the combination rather than to cagrilintide alone.

What Are the Limits of the Current Evidence?

Four limits deserve to be stated plainly. First, essentially the entire trial program was funded and run by the developer, which is normal for an investigational compound but means independent replication does not yet exist. Second, the phase 3 data are dominated by the semaglutide combination, so the standalone contribution of cagrilintide at phase 3 scale is still being isolated in the RENEW program. Third, long-term cardiovascular outcomes data are not yet available; a dedicated outcomes trial remains in progress. Fourth, and most important for anyone encountering this compound outside a trial: cagrilintide is not an approved medicine, alone or in combination, in any jurisdiction as of November 2026. Its legitimate settings are registered clinical research and laboratory research.

How Do Researchers Verify Cagrilintide Material?

Cagrilintide's engineering makes analytical verification more, not less, important. The molecule is a modified 37-residue peptide carrying a fatty-acid side chain, so two checks matter. Mass spectrometry should confirm the intact acylated molecule at its expected mass, distinguishing complete cagrilintide from material missing the side chain or carrying sequence errors. Reversed-phase HPLC provides the purity figure, separating the main peak from deletion sequences and deamidated or oxidized variants that acylated peptides can accumulate.

The working standard is a batch-specific Certificate of Analysis tying those two results to the exact batch supplied. NUPEPS PEPTIDES publishes batch Certificates of Analysis at nupeps.com/coas and tests every batch for purity, quantity, and sterility; our guide to reading a peptide COA walks through how to audit one. For a compound whose research value lies in a precise molecular modification, an unverified vial is an uncontrolled variable.

Cagrilintide Research Material at NUPEPS PEPTIDES

NUPEPS PEPTIDES supplies cagrilintide as a lyophilized research material, Cagrilintide 10MG, for laboratory and in vitro research use only, with a batch Certificate of Analysis available for the material supplied. It is an investigational compound and a research chemical; it is not a medicine, and it is not for human or veterinary use.

Frequently Asked Questions

Is cagrilintide approved?

No. As of November 2026, cagrilintide is not approved as a medicine anywhere, either alone or in the CagriSema combination. Novo Nordisk filed CagriSema with the FDA in December 2025 and the application was still under review at the time of writing. Outside registered trials, cagrilintide exists as a laboratory research compound.

Is cagrilintide the same as semaglutide?

No. Semaglutide is a GLP-1 receptor agonist based on the gut hormone GLP-1. Cagrilintide is based on a different hormone, amylin, and acts at amylin and calcitonin receptors. The two are studied together in the fixed combination CagriSema precisely because their pathways are complementary rather than identical.

Why is cagrilintide studied on a once-weekly schedule?

Because of its engineering. A C20 fatty-acid side chain lets cagrilintide bind reversibly to albumin in the blood, which stretches its half-life to roughly 159 to 195 hours, about a week. Native amylin, by contrast, is cleared in minutes, which is the problem the analogue was designed to solve.

What did cagrilintide do on its own in trials?

In the phase 2 dose-finding trial published in The Lancet in 2021, once-weekly cagrilintide monotherapy produced dose-dependent mean weight reductions of about 6.0 to 10.8 percent over 26 weeks, versus about 3.0 percent on placebo. A dedicated phase 3 monotherapy program is under way but has not yet reported.

How can a researcher verify cagrilintide purity and identity?

Through the batch Certificate of Analysis. Mass spectrometry should confirm the intact acylated molecule at its expected mass, and HPLC should document purity of at least 99 percent for the batch supplied. Certificates for NUPEPS PEPTIDES batches are published at nupeps.com/coas.

Conclusion

Cagrilintide is best understood as an engineering answer to a pharmacology problem: amylin's satiety signaling was well understood for decades, but the hormone itself aggregated and vanished too quickly to build on. Sequence editing plus albumin-binding acylation turned it into a once-weekly molecule with a genuine randomized-trial record, first alone in phase 2 and then, at larger scale, in combination with semaglutide.

The record also has clear edges: sponsor-run trials, a combination-heavy phase 3, outcomes data still pending, and no approval anywhere as of November 2026. For laboratory researchers, cagrilintide remains a precision tool for studying amylin-receptor biology, provided the material is verified the way its design demands: identity by mass spectrometry, purity by HPLC, and a Certificate of Analysis for the batch in hand. This article is educational material about a research compound and is not medical advice.